<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797247</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-005</org_study_id>
    <nct_id>NCT04797247</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction</brief_title>
  <acronym>LIBerate-CVD</acronym>
  <official_title>Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of&#xD;
      LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients&#xD;
      with very-high risk for CVD on a stable diet and oral LDL-C lowering drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, Phase 3 study of 52 weeks duration.&#xD;
&#xD;
      Patients who fulfill the inclusion and exclusion criteria will be enrolled at up to 60 sites&#xD;
      in the United States, Canada, Europe, South Africa, Asia, Australasia, and the Middle East.&#xD;
      Patients will be randomized in a 2:1 ratio to LIB003 or placebo. The total study duration&#xD;
      will be up to 63 weeks which includes up to a Screening Period and 52 weeks of study drug&#xD;
      treatment. Following randomization patients will be dosed and seen in the clinic Q4W (≤31&#xD;
      days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double blind, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>participants, study staff, investigator and sponsor blinded to treatment and lipid levels</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C change compared to placebo</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in LS mean from baseline compared to placebo in LDL-C level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean LDL-C change at week 50 and 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in LS mean from baseline compared to placebo in LDL-C level at Weeks 50 and 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities as severe, moderate or mild after 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluation of Adverse Events based on MedRA based on ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free PCSK9 change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change in LS mean from baseline compared to placebo in free PCSK9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving 2019 ESC/EAS LDL-C goals</measure>
    <time_frame>52 weeks</time_frame>
    <description>To assess the effects of LIB003 on the percentage of patients achieving an LDL-C &lt;40 mg/dL, 55 mg/dL, &lt;70 mg/dL, and 100 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hyper-LDL-cholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg subcutaneously monthly (Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo subcutaneously monthly (Q4W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written and signed informed consent prior to any study-specific&#xD;
             procedure;&#xD;
&#xD;
          -  Male or female ≥18 years of age at the first Screening Visit;&#xD;
&#xD;
          -  Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥17 and ≤42 kg/m2;&#xD;
&#xD;
          -  At very high risk for CVD which includes history of CVD, (including cerebrovascular or&#xD;
             peripheral arterial disease) or very high risk as defined in the 2019 ESC/EAS&#xD;
             Guidelines&#xD;
&#xD;
          -  At Screening or post Washout/Stabilization), ≥70 mg/dL and TG ≤400 mg/dL while on&#xD;
             stable lipid-lowering oral drug therapy (i.e., maximally tolerated statin with or&#xD;
             without ezetimibe); Patients unable to tolerate approved doses of a statin may take&#xD;
             lower than approved doses and dose less frequently than daily as long as the dose and&#xD;
             dosing frequency is consistent; Patients with documentation of inability to tolerate&#xD;
             any statin at any dose, or history of rhabdomyolysis, may also participate;&#xD;
&#xD;
          -  On a stable diet and lipid-lowering oral therapies (such as statins, ezetimibe,&#xD;
             bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic acid, and&#xD;
             bempedoic acid) or combinations thereof for at least 4 weeks&#xD;
&#xD;
          -  Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a&#xD;
             washout period of ≥4 weeks after the last dose; for those on 300 mg or 420 mg Q4W (≤31&#xD;
             days) the washout period is ≥8 weeks following last dose; 8. Females of childbearing&#xD;
             potential must be using a highly effective form of birth control if sexually active&#xD;
             and have a negative urine pregnancy test at the last Screening Visit;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of prohibited oral lipid-lowering agents mipomersen or lomitapide within 6 months&#xD;
             of screening, gemfibrozil within 6 weeks of screening, LDL or plasma apheresis within&#xD;
             2 months prior to randomization; received other investigational agent(s) such as PCSK9&#xD;
             or Lp(a) siRNA or locked nucleic acid-reducing agents within 12 months of the&#xD;
             Screening Visit;&#xD;
&#xD;
          -  Documented history of HoFH defined clinically or genetically&#xD;
&#xD;
          -  History of any prior or active clinical condition or acute and/or unstable systemic&#xD;
             disease compromising patient inclusion, at the discretion of the Investigator&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active, not using or unwilling to&#xD;
             use a highly effective form of contraception, pregnant or breastfeeding, or who have a&#xD;
             positive urine pregnancy test at the last Screening Visit;&#xD;
&#xD;
          -  Moderate to severe renal dysfunction, defined as an eGFR &lt;30 mL/min/1.73m2&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction, history of liver transplant, and/or ALT&#xD;
             or AST &gt;2.5 × the ULN as determined by central laboratory analysis at screening&#xD;
&#xD;
          -  Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism 9. Uncontrolled Type 1&#xD;
             or Type 2 DM, defined as FBS ≥200 mg/dL or HbA1C ≥9%; 10. Uncontrolled serious cardiac&#xD;
             arrhythmia, MI, unstable angina, PCI, CABG, placement of implantable cardioverter&#xD;
             defibrillator or biventricular pacemaker, aortic valve surgery, or stroke within 3&#xD;
             months prior to the Screening Visit; 11. Planned cardiac surgery or revascularization;&#xD;
             12. New York Heart Association class III-IV heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lerodalcibep</keyword>
  <keyword>PCSK9 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

